Limits...
Lifestyle intervention is associated with decreased concentrations of circulating pentraxin 3 independent of CRP decrease.

Larsson A, Ronquist G, Åkerfeldt T - Ups. J. Med. Sci. (2013)

Bottom Line: Wilcoxon paired samples test showed a significant decrease in PTX3 concentrations from 2068 pg/mL at start to 2007 pg/mL at 4 weeks (P = 0.002) and 1748 pg/mL at 8 weeks (P = 0.003).The PTX3 decrease was not significantly correlated with a corresponding decrease in CRP or weight reduction.The lifestyle intervention program resulted in a significant reduction of circulating concentrations of pentraxin 3 already after 4 and 8 weeks of treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

ABSTRACT

Objectives: Pentraxin 3 (PTX3) is an acute phase marker, which is produced at the site of infection or inflammation in contrast to CRP that is mainly synthesized by the liver. The aim of the present study was to see if lifestyle interventions/weight loss would lead to decreased blood plasma concentrations of PTX3.

Methods: Study subjects (n = 31) were recruited to a lifestyle intervention program aiming at increased physical activity, improved eating habits, and weight loss. High-sensitivity C-reactive protein (CRP) and PTX3 methods were used for analysis of CRP and PTX3 in plasma samples collected at inclusion and after 4 and 8 weeks of treatment.

Results: Wilcoxon paired samples test showed a significant decrease in PTX3 concentrations from 2068 pg/mL at start to 2007 pg/mL at 4 weeks (P = 0.002) and 1748 pg/mL at 8 weeks (P = 0.003). The PTX3 decrease was not significantly correlated with a corresponding decrease in CRP or weight reduction.

Conclusions: The lifestyle intervention program resulted in a significant reduction of circulating concentrations of pentraxin 3 already after 4 and 8 weeks of treatment.

Show MeSH

Related in: MedlinePlus

Pentraxin 3 in individual patients at start, and after 4 weeks and 8 weeks of lifestyle intervention.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3713381&req=5

Figure 1: Pentraxin 3 in individual patients at start, and after 4 weeks and 8 weeks of lifestyle intervention.

Mentions: Median blood plasma CRP decreased from 1.32 mg/L (interquartile range 0.51–2.17) at start to 1.21 mg/L (0.49–1.64; P = 0.27) after 4 weeks and 1.08 mg/L (0.62–1.59; P = 0.66) after 8 weeks. The CRP decrease after 4 weeks was significantly associated with the concomitant weight reduction (n = 26; Spearman R = 0.71; P = 0.00005) and after 8 weeks (n = 26; R = 0.67; P = 0.00018). Median plasma PTX3 values decreased from 2068 pg/mL (interquartile range 1800–2904) at start to 2007 pg/mL 1544–2422 after 4 weeks and 1748 pg/mL 1044–2188 after 8 weeks (Figure 1). In comparison with values at start, plasma PTX3 concentration was significantly reduced after 4 weeks (P = 0.002) and after 8 weeks (P = 0.003).


Lifestyle intervention is associated with decreased concentrations of circulating pentraxin 3 independent of CRP decrease.

Larsson A, Ronquist G, Åkerfeldt T - Ups. J. Med. Sci. (2013)

Pentraxin 3 in individual patients at start, and after 4 weeks and 8 weeks of lifestyle intervention.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3713381&req=5

Figure 1: Pentraxin 3 in individual patients at start, and after 4 weeks and 8 weeks of lifestyle intervention.
Mentions: Median blood plasma CRP decreased from 1.32 mg/L (interquartile range 0.51–2.17) at start to 1.21 mg/L (0.49–1.64; P = 0.27) after 4 weeks and 1.08 mg/L (0.62–1.59; P = 0.66) after 8 weeks. The CRP decrease after 4 weeks was significantly associated with the concomitant weight reduction (n = 26; Spearman R = 0.71; P = 0.00005) and after 8 weeks (n = 26; R = 0.67; P = 0.00018). Median plasma PTX3 values decreased from 2068 pg/mL (interquartile range 1800–2904) at start to 2007 pg/mL 1544–2422 after 4 weeks and 1748 pg/mL 1044–2188 after 8 weeks (Figure 1). In comparison with values at start, plasma PTX3 concentration was significantly reduced after 4 weeks (P = 0.002) and after 8 weeks (P = 0.003).

Bottom Line: Wilcoxon paired samples test showed a significant decrease in PTX3 concentrations from 2068 pg/mL at start to 2007 pg/mL at 4 weeks (P = 0.002) and 1748 pg/mL at 8 weeks (P = 0.003).The PTX3 decrease was not significantly correlated with a corresponding decrease in CRP or weight reduction.The lifestyle intervention program resulted in a significant reduction of circulating concentrations of pentraxin 3 already after 4 and 8 weeks of treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

ABSTRACT

Objectives: Pentraxin 3 (PTX3) is an acute phase marker, which is produced at the site of infection or inflammation in contrast to CRP that is mainly synthesized by the liver. The aim of the present study was to see if lifestyle interventions/weight loss would lead to decreased blood plasma concentrations of PTX3.

Methods: Study subjects (n = 31) were recruited to a lifestyle intervention program aiming at increased physical activity, improved eating habits, and weight loss. High-sensitivity C-reactive protein (CRP) and PTX3 methods were used for analysis of CRP and PTX3 in plasma samples collected at inclusion and after 4 and 8 weeks of treatment.

Results: Wilcoxon paired samples test showed a significant decrease in PTX3 concentrations from 2068 pg/mL at start to 2007 pg/mL at 4 weeks (P = 0.002) and 1748 pg/mL at 8 weeks (P = 0.003). The PTX3 decrease was not significantly correlated with a corresponding decrease in CRP or weight reduction.

Conclusions: The lifestyle intervention program resulted in a significant reduction of circulating concentrations of pentraxin 3 already after 4 and 8 weeks of treatment.

Show MeSH
Related in: MedlinePlus